Nanjing BioPoint® Diagnostic Technology Co. Ltd. will contrentrate its research efforts in developing Point of Care (POC) rapid diagnostic product.
Point of care tests (POCT) have gained increasingly wide usage over the last 20 years. It has many forms but in general a true point of care test can be performed with a simple device, a strip or a cartridge for instance. The test sample, such as urine, saliva or finger-prick blood, is easily gathered from the person to be tested without the requirement of elaborate preparation.
The results of POCT tests need to be obtainable at the point of the test within a short period of time, often no more than a few tens of minutes. The commercially successful tests often present the results with some clear visual indications on the testing strip which can be very easily interpreted. There are tests which provide a “yes” or “no” answer to certain conditions (e.g. pregnancy test) as well as tests which provide quantitative results, sometimes obtained by using a small electronic instrument (e.g. blood sugar test).
The nature of the POCT test makes it particularly suitable for home health care and for public health programs in areas with limited access to sophisticated testing instruments. Because the testing strips or cartridges can often be stored at room temperature with long shelf life, and because the test can often be performed with minimum amount of training, the tests can be performed at the location of clinics close to where patients live. The quick return of the testing result means it can be communicated instantly to the patient during the same visit to a healthcare facility, instead of asking those in need of tests to return a second time for the results. Since these tests do not require sophisticated laboratory equipment, they are often the only viable solution for health programs in remote or resource poor areas.
The other major benefit of the POCT test is it is suited for mass production. The unit cost can be quite low. It is a cost effective way of reducing public health spending therefore the method has increasingly attracted the attention from the agencies which implement large scale public health programs, such as WHO and MSF etc.
The founder and chief executive of Nanjing BioPoint®, Prof. David Anderson, together with his team at the Burnet Institute in Melbourne, Australia have had a long, successful track record of developing POCT tests. Those have been successfully commercialized including the test for hepatitis E virus, active syphilis and for testing CD4 T cells in HIV/AIDS patients.